204 related articles for article (PubMed ID: 34378812)
1. Real-world effectiveness of adalimumab in patients with moderate-to-severe hidradenitis suppurativa: the 1-year SOLACE study.
Gulliver W; Alavi A; Wiseman MC; Gooderham MJ; Rao J; Alam MS; Papp KA; Desjardins O; Jean C
J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2431-2439. PubMed ID: 34378812
[TBL] [Abstract][Full Text] [Related]
2. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):755-762. PubMed ID: 37331620
[TBL] [Abstract][Full Text] [Related]
3. The Effectiveness of Guselkumab in Patients With Hidradenitis Suppurativa Under Clinical Practice Conditions: A Spanish Multicentre Retrospective Study.
Rivera-Díaz R; Pozo T; Alfageme F; Díaz Ley B; Osorio GF; Chico R; Vilarrasa E; Silvente C; Ciudad Blanco C; Romaní J; Martorell A; Fernández P; Romero Ferreiro C; Molina Leyva A
Actas Dermosifiliogr; 2023 Oct; 114(9):T755-T762. PubMed ID: 37479135
[TBL] [Abstract][Full Text] [Related]
4. Improved clinical effectiveness of adalimumab when initiated with clindamycin and rifampicin in hidradenitis suppurativa.
Aarts P; van Huijstee JC; van der Zee HH; van Straalen KR; Prens EP
J Eur Acad Dermatol Venereol; 2024 May; 38(5):904-909. PubMed ID: 38112226
[TBL] [Abstract][Full Text] [Related]
5. Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC; Passeron T; Pariser D; Wozniak MB; Li X; Uhlmann L; Lobach I; Martinez AL; Ravichandran S; Alarcon I; Offidani A; Alam MS; Mendes-Bastos P
Br J Dermatol; 2024 May; 190(6):836-845. PubMed ID: 38470171
[TBL] [Abstract][Full Text] [Related]
6. Impact of Single Nucleotide Polymorphisms of the Promoter of the TNF Gene on Adalimumab Treatment Responses in Hidradenitis Suppurativa.
Argyropoulou M; Trigoni A; Kaffenberger J; Stergianou D; Damoraki G; Mingiani E; Micha S; Krispinsky A; Meltzanidou P; Kanni T; Lazaridou E; Giamarellos-Bourboulis EJ
Dermatology; 2023; 239(5):746-752. PubMed ID: 37331331
[TBL] [Abstract][Full Text] [Related]
7. A systematic review of Janus kinase inhibitors and spleen tyrosine kinase inhibitors for Hidradenitis suppurativa treatment.
Heidari A; Ghane Y; Heidari N; Sadeghi S; Goodarzi A
Int Immunopharmacol; 2024 Jan; 127():111435. PubMed ID: 38150881
[TBL] [Abstract][Full Text] [Related]
8. Real-world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: A 52-week analysis of a postmarketing surveillance study in Japan.
Hayashi N; Hayama K; Takahashi K; Kurokawa I; Okazaki M; Kashiwagi T; Iwashita E; Terui T
J Dermatol; 2023 Aug; 50(8):1034-1044. PubMed ID: 37264993
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and Safety of the Heat Shock Protein 90 Inhibitor RGRN-305 in Hidradenitis Suppurativa: A Parallel-Design Double-Blind Trial.
Ben Abdallah H; Bregnhøj A; Emmanuel T; Ghatnekar G; Johansen C; Iversen L
JAMA Dermatol; 2024 Jan; 160(1):63-70. PubMed ID: 38055242
[TBL] [Abstract][Full Text] [Related]
10. B-cell and complement signature in severe hidradenitis suppurativa that does not respond to adalimumab.
Hambly R; Gatault S; Smith CM; Iglesias-Martinez LF; Kearns S; Rea H; Marasigan V; Lynam-Loane K; Kirthi S; Hughes R; Fletcher JM; Kolch W; Kirby B
Br J Dermatol; 2023 Jan; 188(1):52-63. PubMed ID: 36689500
[TBL] [Abstract][Full Text] [Related]
11. External Validation of the IHS4-55 in a European Antibiotic-Treated Hidradenitis Suppurativa Cohort.
van Straalen KR; Tzellos T; Alavi A; Benhadou F; Cuenca-Barrales C; Daxhelet M; Daoud M; Efthymiou O; Giamarellos-Bourboulis EJ; Guillem P; Gulliver W; Jemec GBE; Katoulis A; Koenig A; Lazaridou E; Lowes MA; Marzano AV; Matusiak L; Molina-Leyva A; Moltrasio C; Pinter A; Potenza C; Prens EP; Romaní J; Saunte DM; Sayed C; Skroza N; Stergianou D; Szepietowski JC; Trigoni A; Vilarrasa E; Kyrgidis A; Zouboulis CC; van der Zee HH
Dermatology; 2023; 239(3):362-367. PubMed ID: 36630943
[TBL] [Abstract][Full Text] [Related]
12. Brodalumab for moderate-severe hidradenitis suppurativa: An open-label multicentric cohort study in real clinical practice.
Osorio-Gómez GF; Ortiz-Álvarez J; Diaz-Ceca D; Guijarro-Sánchez C; Conejo-Mir Sánchez J; Fernández Crehuet P
Australas J Dermatol; 2024 May; 65(3):254-259. PubMed ID: 38597096
[TBL] [Abstract][Full Text] [Related]
13. S2k guideline for the treatment of hidradenitis suppurativa / acne inversa - Short version.
Zouboulis CC; Bechara FG; Fritz K; Goebeler M; Hetzer FH; Just E; Kirsten N; Kokolakis G; Kurzen H; Nikolakis G; Pinter A; Podda M; Rosinski K; Schneider-Burrus S; Taube KM; Volz T; Winkler T; Kristandt A; Presser D; Zouboulis VA
J Dtsch Dermatol Ges; 2024 Jun; 22(6):868-889. PubMed ID: 38770982
[TBL] [Abstract][Full Text] [Related]
14. Longitudinal observational study of hidradenitis suppurativa: impact of surgical intervention with adjunctive biologic therapy.
Shanmugam VK; Mulani S; McNish S; Harris S; Buescher T; Amdur R
Int J Dermatol; 2018 Jan; 57(1):62-69. PubMed ID: 29130482
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of a combined pharmacological and surgical approach in patients affected by hidradenitis suppurativa: data from a retrospective real-world clinical study.
Malvaso D; Chiricozzi A; Fossati B; Antonelli F; Peris K
Ital J Dermatol Venerol; 2024 Apr; 159(2):190-195. PubMed ID: 38650499
[TBL] [Abstract][Full Text] [Related]
16. Secukinumab in Hidradenitis Suppurativa Patients Who Failed Adalimumab: A 52-Week Real-Life Study.
Martora F; Marasca C; Cacciapuoti S; Fariello F; Potestio L; Battista T; Scalvenzi M; Megna M
Clin Cosmet Investig Dermatol; 2024; 17():159-166. PubMed ID: 38283798
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study.
Kirby JS; Okun MM; Alavi A; Bechara FG; Zouboulis CC; Brown K; Santos LL; Wang A; Bibeau KB; Kimball AB; Porter ML
J Am Acad Dermatol; 2024 Mar; 90(3):521-529. PubMed ID: 37871805
[TBL] [Abstract][Full Text] [Related]
18. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review.
Guermazi D; Shah A; Yumeen S; Saliba E
Arch Dermatol Res; 2024 May; 316(6):259. PubMed ID: 38795234
[TBL] [Abstract][Full Text] [Related]
19. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: A randomized, double-blind, placebo-controlled clinical trial.
Alavi A; Prens E; Kimball AB; Frew JW; Krueger JG; Mukhopadhyay S; Gao H; Ranganathan U; Ivanoff NB; Hernandez Daly AC; Zouboulis CC
Br J Dermatol; 2024 Apr; ():. PubMed ID: 38576350
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of radiofrequency in the treatment of hidradenitis suppurativa; a systematic review.
Nilforoushzadeh MA; Heidari N; Heidari A; Ghane Y; Hosseini S; Lotfi Z; Jaffary F; Nobari MN; Aghamiri ZS; Nobari NN
Lasers Med Sci; 2024 May; 39(1):139. PubMed ID: 38795173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
